Time Matters in Generalized Myasthenia Gravis

Improving Timely Access to Targeted Therapies CME/CNE

Thursday, October 30, 2025 | 11:30 AM - 12:30 PM TZ
event presence logo
Supported by an independent educational grant from Alexion Pharmaceuticals, Inc.

overview

This expert discussion brings together leading neurologists to explore the evolving landscape of myasthenia gravis (MG) diagnosis and treatment. The conversation will explore the physical, psychological, and social dimensions of patient burden, emphasizing the importance of timely diagnosis and individualized care strategies. With the emergence of targeted immunotherapies and advances in disease-modifying treatments, neurologists now have new tools to address both symptoms and disease progression. Experts will discuss the effectiveness, safety, and accessibility of these therapies, alongside the practical challenges of integrating them into routine care. This session aims to deepen understanding of patient needs and improve therapeutic decision-making, fostering an approach to MG management that prioritizes both clinical outcomes and patient-reported experiences.

This activity is not part of the official scientific program of AANEM.

faculty

Moderator

Jaishri Blakeley, MD

Faculty Affiliations Line One

Faculty Affiliations Line Two

Faculty Affiliations Line Three

PANELIST

Michael Fisher, MD

Faculty Affiliations Line One

Faculty Affiliations Line Two

Faculty Affiliations Line Three

PANELIST

Richard Madonna, MD

Faculty Affiliations Line One

Faculty Affiliations Line Two

Faculty Affiliations Line Three

AGENDA

1:00 PM TZ

Welcome and Introduction

John Doe, MD

1:30 PM TZ

Introduction Medical Term

Lynn Doe, MD

2:00 PM TZ

Management of Acute Leukemia for the Community Healthcare Team

Jane Doe, MD

2:30 PM TZ

Panel Discussion

Kelly Doe, MD

5:00 PM TZ

Audience Q&A

TARGET AUDIENCE

This educational activity is intended for an audience of neurologists, pediatricians, primary care physicians, physician assistants, nurses, and pharmacists in the United States.

GOAL STATEMENT

The goal of this activity is for learners to be better able to utilize FDA-approved targeted therapies for generalized myasthenia gravis (gMG) in a timely manner and in a way that maximizes efficacy and safety.

LEARNING OBJECTIVES

[bold]Upon completion of this activity, participants will:[/bold] [para]Have increased knowledge regarding the:[/para] [list][item] Symptom burden associated with gMG  [item]Clinically relevant factors that inform the timely selection of targeted therapies for the management of gMG   [item]Clinical recommendations for minimizing adverse events associated with the use of targeted therapies for the management of gMG  [/list] [para]Demonstrate greater confidence in their ability to [/para] [list][item]Personalize the selection of targeted therapies for the management of gMG [/list]

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
accreditation logo
medscape logo
[title]For Physicians[/title] [text]Medscape, LLC designates this live activity for a maximum of 1.0 [bold][italic]AMA PRA Category 1 Credit(s)[/italic][super]TM[/super][/bold]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.[/text] [break] [title]For Nurses[/title] [text]Awarded up to 1.0 contact hour(s) of nursing continuing professional development for RNs and APNs.[/text]
© 2025 MedscapeLIVE! All Rights Reserved | Medscape Education Terms of Service | Privacy Policy